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Summary Prostate-specific membrane antigen (PSM) is a glycoprotein recogmsed by the prostate-specific
monoclonal antibody 7E11-C5. which was raised against the human prostatic carcinoma cell line LNCaP. A
cDNA clone for PSM has been described. PSM is of clinical importance for a number of reasons.
Radiolabelled antibody is being evaluated both as an imaging agent and as an immunotherapeutic in prostate
cancer. Use of the PSM promoter has been advocated for gene therapy applications to drive prostate-specific
gene expression. Although PSM is expressed in normal prostate as well as in primary and secondary prostatic
carcinoma, different splice variants in malignant tissue afford the prospect of developing reverse transcrip-
tion-polymerase chain reaction (RT-PCR)-based diagnostic screens for the presence of prostatic carcinoma
cells in the circulation. We have undertaken characterisation of the gene for PSM in view of the protein's
interesting characteristics. Unexpectedly. we have found that there are other sequences apparently related to
PSM in the human genome and that PSM genomic clones map to two separate and distinct loci on human
chromosome 11. Investigation of the function of putative PSM-related genes will be necessary to enable us to
define fully the role of PSM itself in the development of prostatic carcinoma and in the clinical management of
this malignancv.
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Prostate cancer is a major clinical challenge, with an
incidence of some 134 000 new cases in the USA in 1994 and
an expected overall annual mortality of 38 000 in that
country alone. Progression of the disease is unpredictable,
but 5 year survival rates for those with metastatic disease are
low (Coffey, 1993). The mainstay of therapy remains removal
of androgenic drive whether by orchidectomy or by phar-
macological intervention (Chiarodo, 1991). The role of
radical prostatectomy remains controversial. Clinical man-
agement is facilitated by the availability of diagnostic tests
for prostatic acid phosphatase (PAP) and prostate-specific
antigen (PSA). PSA is particularly useful in that it correlates
to some extent with tumour burden and provides a relatively
sensitive marker of response to surgery, radiotherapy or and-
rogen ablation therapy in prostate cancer patients. It is also a
sensitive indicator of disease relapse. Both PAP and PSA are
secreted proteins detectable in the serum.
Recently an additional prostate-specific marker has been
described (Horoszewicz et al., 1987). This protein has been
termed prostate-specific membrane antigen (PSM). It was
originally defined by using the human prostate cancer cell
line LNCaP (which was originally derived from a metastatic
lymph node) as an immunogen to generate mouse mono-
clonal antibodies (Horoszewicz et al., 1983). One such
antibody, designated 7Ell-C5 or Cyt-356, binds strongly to
the membranes of LNCaP cells (Lopes et al., 1990). This
antibody was used to immunoprecipitate PSM from LNCaP
cells. Peptide microsequencing allowed a cDNA clone to be
obtained (Israeli et al.. 1993). The cDNA clone encodes a
protein of 750 amino acids with a predicted molecular weight
of 84 000. The protein is glycosylated in vivo with an appar-
ent molecular weight of 100.5 kDa on Western blotting
(Abdel-Nabi et al.. 1992). It is thought that the epitope
recognised by the Cyt-356 antibody includes a carbohydrate
portion of the PSM (Troyer et al., 1993, 1994). It might be
argued that an antibody recognising only PSM protein
epitopes would be ideal for potential clinical applications in
that it would avoid the possibility of cross-reactivity with
similar carbohydrate side chains on unrelated proteins.
PSM is a type II membrane protein with a short cytoplas-
mic N-terminal region, a 24 amino acid transmembrane
domain and a 707 amino acid extracellular C-terminal por-
tion. A 149 amino acid domain in the extracellular portion of
the molecular (residues 418-567) demonstrates strong
homology with the human transferrin receptor (Keer et al.,
1990; Rossi and Zetter, 1992). The significance of this re-
mains unclear. Most type II membrane antigens are either
transport proteins, membrane-associated proteases or binding
proteins (Parks and Lamb, 1991). PSM is expressed in
primary and metastatic prostatic tumour tissue and to some
extent in normal prostate epithelium. Only low levels of the
antigen are apparently expressed in benign prostatic hyper-
trophy (Israeli et al., 1994).
In view of the potential diagnostic (Lopes et al., 1990;
Wynant et al., 1991; Rochon et al., 1994) and therapeutic
(Axelrod et al., 1992) applications of this protein, we under-
took the characterisation of the gene which encodes it. In this
paper, we demonstrate that there are two distinct genetic loci
on human chromosome 11 which hybridise with PSM
genomic clones. Fluorescence in situ hybridisation (FISH)
analysis places these two loci at Ilcen-pI2 and 1lql4
respectively. Southern blotting studies with fragments of the
cDNA sequence are also consistent with more than a single
gene copy. Chromosome sublocalisation studies and the in
situ PCR (PRINS) technique suggest that the lpl1.2 locus is
probably the site of the gene expressing the currently known
PSM.
Materials and methods
PSM genomic clones
PCR primers were designed based upon published cDNA
sequence of PSM (Israeli et al., 1993). Primer pair IA and lB
(dATGTGGAATCTCCTTCACGAAACC and dTATAAA-
CCACCCGAAGAGGAAGCC) amplified a 129 base pair
product from human genomic DNA as predicted. The PSM
gene contains at least four introns which are not predicted to
interrupt this PCR product (unpublished results and Heston.
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1994). PCR was performed as follows: samples of genomic
DNA (150 ng) were amplified in a cycle of 95°C for 1 min.
60'C for 1 min and 72'C for 2 min for 30 cycles using 1 unit
of Taq DNA polymerase (Promega). 1.5 mM magnesium
chloride, 0.25 ILM oligonucleotides and 200 jiM dNTPs. PCR
products were analysed on 2% agarose gels and visualised
under UV light with ethidium bromide staining. The primer
pair IA and 1B was used to screen a yeast artificial
chromosome (YAC) library as described by Anand et al.
(1990). The YAC 13BE6 was identified and used for further
analysis.
Chromosome localisation
Primer pair IA and lB was used to screen the National
Institute of General Medical Sciences (NIGMS) rodent
somatic cell hybrid mapping panel number 2 (Coriell Ins-
titute for Medical Research, Camden, NJ. USA) using PCR
conditions as described above. The only positive signal
obtained was with the cell line GM10927A. consistent with
localisation to human chromosome 11.
Chromosome sub-localisation
PCR screening of a number of cell lines containing fragments
of human chromosome 11 on rodent backgrounds was then
undertaken. Cell lines analysed were GM1 1936, GM07298.
GM 11943. GM 11222. GM 10482. GM11944 and GM11939
(NIGMS Mutant Cell Repository). Positive signals were only
obtained with cell lines GM1 1944. GM1 1943, GM1 1222 and
GM 10482. This localises the PSM gene to the region between
llqll and llpll.2.
Southern blotting
Human genomic DNA (5 jg) from seven unrelated individ-
uals was digested separately with four restriction enzymes
(MspI. BanII. PalI. StvI) according to the manufacturers'
instructions. Restriction fragments were fractionated in a 1 %
agarose 1 x TBE gels for 18 hours 50 Volts and transferred
to nylon membranes (Hybond>; Amersham International) by
Southern blotting. The 129 bp PCR product amplified by
primers IA and 1B was radiolabelled to a specific activity of
approximately 1 x 109 d.p.m. ig-' DNA by random primer
labelling and hybridised to Southern blots. Hybridisation was
performed in 6 x SSC. 5 x Denhardt's solution, 0.5% SDS,
100 ig ml-' salmon sperm DNA at 65'C overnight. Filters
were washed to a final stringency of 1 x SSC'0.1% SDS at
65'C for I h. Autoradiography was overnight at - 70°C with
an intensifying screen.
Probe preparation
YAC clone 13BE6 was propagated on synthetic dextrose
agar at 30'C and a single pure colony from this grown to
saturation in SD broth, also at 30°C. Cells were harvested.
treated with Zymolase lOOT (ICN Biochemicals) and lysed
with 5 m potassium acetate. After ethanol precipitation the
DNA was resuspended in TE buffer, pH 7.4. and treated
with RNAse A and proteinase K. Two phenol-chloroform
extractions were performed and the sample reprecipitated.
The DNA was resuspended in water and the concentration
estimated by spectrophotometry.
The probe was biotinylated using Biotin-High Prime
(Boehringer). Human Cot-I DNA. 20 jg (Gibco BRL), and
sonicated herring sperm DNA, 5 jig (Promega), were added
before ethanol precipitation. The DNA was resuspended in
hybridisation buffer containing 50% formamide/2 x SSC/
10% dextran sulphate. pH 7.0. To remove by competition
any repeat sequences that might be present, the probe cock-
tail was denatured at 75'C for 10 min and incubated at 37°C
for 3 h (Landegent et al.. 1987).
Fluorescent in situ hvbridisation (FISH)
Hybridisation and detection was performed using a modified
version of the technique originally described by Pinkel et al.
(1986). Metaphase spreads were prepared from cultured
human peripheral blood lymphocytes and, after fixation.
pretreated with RNAse, pepsin and 0.1 mm magnesium
chloride in buffered formalin before being denatured at 75'C
for 5 mmn in 70% formamide 2 x SSC, pH 7.0. Hybridisation
with probe was allowed to proceed for 12-16 h at 37C
under a sealed coverslip in a moist chamber followed by
three washes with 0.1 x SSC, pH 7.0, at 60°C. Before addi-
tion of fluorescein isothiocyanate (FITC)-conjugated avidin
cell sorting grade (Vector Laboratories) the spreads were
incubated with 0.5% blocking agent (Boehringer) for 5 min
at room temperature. Signal amplification was by addition of
biotinylated anti-avidin (Vector Laboratories) and a further
incubation with FITC-avidin DCS. Slides were then washed
with phosphate-buffered saline (PBS), dehydrated, air dried
and mounted in Vectashield anti-fade medium (Vector
Laboratories) containing DAPI at a final concentration of
1.5 igmi-1.
Microscopy was performed using a Zeiss Axioskop fluor-
escence microscope coupled to a CCD camera and image
analysis system (Applied Imaging International).
In situ PCR (PRIVNS)
PRINS was performed essentially according to the method of
Koch et al. (1993) as follows. Metaphase spreads, prepared
as previously described. were used directly after fixation with-
out further pretreatment. The reaction mixture, preheated to
95'C for 5 mmn before use, contained 4 jig each of pnrmer IA
and lB, 2.5 mM magnesium chloride. dATP, dCTP. dGTP to
a final concentration of 0.2mM each and digoxigenin-11-
dUTP (Boehringer) to a final concentration of 0.1 mM.
Immediately before transferring the reaction mixture to a
prewarmed (95°C, 10 mmn) coverslip, I unit of Taq DNA
polymerase was added. A preheated slide (95C, 10 mmn) was
lowered onto the coverslip and, after inverting, the coverslip
was sealed with rubber cement. The slide was then incubated
in a moist chamber at 70'C for 3 h, after which time the
reaction was stopped by washing for 2 min at 70'C in 50 mm
sodium chloride, 50 mm EDTA. pH 8.0. Further processing
was as described for the standard FISH procedure, the detec-
tion reagent used being anti-digoxigenin-rhodamine Fab
fragments (Boehringer).
Microscopy and image analysis were as previously des-
cribed.
Results
Chromosome localisation
The results of PCR analysis of the NIGMS mapping panel
number 2 by PCR are illustrated in Figure 1. It is clear that a
single signal is obtained in lane 12 corresponding to the cell
line GM 10927A, which contains human chromosome 11 as
its single human genetic component on a Chinese hamster
background (Kao et al.. 1976).
Chromosome sublocalisation
PCR analysis of a number of cell lines containing fragments
of human chromosome 11 was next performed. The human
component of these various cell lines is illustrated by com-
parison with the ideogram of human chromosome 11 in
Figure 2. Figure 3 shows the results of attempted .PCR
amplification of DNA from these different cell lines. Positive
signals were obtained with cell lines GM 11944, GM11943,
GM11222 and GM10482 (lanes 3, 4, 8 and 9 of Figure 3).
This confirms the localisation of PSM to the region
llqll-llpll.2 (see Figure 2). In view of subsequent FISH
data suggesting a second locus close to 1 1q13.5, positive
control PCR experiments were performed with PCR primers
amplifying the Int-2 oncogene, which maps to 1 1q13. Positive
signals were obtained with the expected cell lines (data not
shown), confirming that PSM would have been detected if
located at the llq locus.
Southern blotting
The 129 bp N-terminal PSM PCR products hybridised to
multiple bands (five or more) on genomic sequence Southern
blots with all four enzymes tested. Data with these two
enzymes are presented in Figure 4. In all cases the bands
identified totalled in excess of 15 kb. The probe used has a
single, internal PaII site, but there are no sites for BanII,
MspI or StyI. Therefore, the probe would only be expected
to hybridise to a single band on genomic Southern blots with
BanII, MspI and StvI, and two bands with Pall, taking into
account the possibility of hybridisation to adjacent intronic
sequences (Heston. 1994) adjoining the 3' end of the probe.
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Yeast artificial chromosome cloning
Primer pair IA and 1B was used to screen the ICI YAC
library (Anand et al.. 1990) using PCR conditions as des-
Figre 3 PCR screening of somatic cell hybrid lines containing
fragments of human chromosome 11. Lanes 1 and 15 contain
size markers; lane 2, blank; lane 3, GM 11944; lane 4. GM1 1943;
lane 5, GM07298; lane 6, GM1 1936; lane 7, GM] 1939; lane 8,
GM1 1222; lane 9, GM 10482; lane 10, blank; lane 11. human
genomic DNA control; lane 12, rodent DNA negative control.
The band size of 129 bp is as expected.
a b
Figure 1 PCR screening of the NIGMS somatic cell hybrid
mapping panel 2. Lanes 1 and 30 contain ¢x174 HaeIII
restricted DNA size markers. Lanes 2-25 are PCRs of somatic
cell hybrids containing human chromosomes 1-22, X and Y
respectively. The expected band of 129 bp is apparent in lane 12
(chromosome 11). Lane 26 contains human genomic DNA cont-
rol; lane 27. mouse DNA negative control; lane 28. no DNA
control.
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Figure 2 Fragments of human chromosome 11 contained in
somatic cell hybrid cell lines screened by PCR for the presence
of PSM. Symbols + and - signify the presence or absence of
PSM in these cell lines.
Figure 4 Southern blot of total human genomic DNA digested
with (a) StvI and (b) Pall and probed with a 129 bp PSM 5' end
fragment. A and B are 10 kb and 5 kb markers respectively.
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cribed above. The Y.AC 13BE6 was identified. This proVides
a 129 bp fragment on PCR amplification identical to that
predicted from the published cDNA sequence and to that
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obtained from total human genomic DNA. YAC 1 3BE6
contains a human insert of 500 kb on pulsed-field gel elect-
rophoresis (data not shown).
Fluorescence in situ hvbridisation
The results of fluorescent in situ hvbridisation (FISH)
analysis (Pinkel et al.. 1986: Landegent et al.. 1987) using
YAC 13BE6 on metaphase spreads are shown in Figure 5.
Two distinct signals are apparent. One is positioned just
above the centromere on the short arm of chromosome 11.
The other is approximately one-third of the way down the
long arm of chromosome 11 in the 1 1q13.5 region. Given the
relatively small size of the PSM gene (less than 10 kb in total.
unpublished results and Heston. 1994) and the large size of
the YAC insert, it is possible that the homology between
these two genetic loci extends beyond the PSM gene itself.
PRINS anal!ysis
The results of in situ PCR amplification of the PSM gene are
illustrated in Figure 6 (Koch et al.. 1993; Long et al., 1993).
In these experiments, a signal was consistently observed
above the centromere of chromosome 11 on the short arm.
This result is consistent with PCR sublocalisation studies and
suggests that the location of the known PSM gene itself is in
fact on human chromosome 11 between 1 Icen and 11 p12,
most probably at llpll.2.
Discussion
The expression profile of PSM has been studied previously in
some detail (Israeli et al.. 1994). The membrane protein is
expressed in primary and metastatic prostatic cancer tissue as
well as in the normal prostate (see below). Expression levels
in benign prostatic hypertrophy are thought to be low.
Northem analysis shows that a 2.6 kb mRNA is expressed in
LNCaP cells but not in either of the prostatic cancer cell
lines DU-145 or PC-3 (Israeli et al.. 1993). Immunohisto-
chemical analysis of these prostatic cancer cell lines is consis-
tent with these data in that LNCaP cells demonstrate exten-
sive staining with the 7EIl-C5.3 antibody. whereas DU-145
and PC-3 cells are both negative (Stone et al.. 1978: Kaign et
al.. 1979). Transfection experiments using PSM expression
plasmids into PC-3 cells show that these cells are capable of
expressing the glycosylated membrane protein. It is not clear
whether the PSM gene has been deleted in the cell lines PC-3
Fvire 5 FISH analysis using YAC I 3BE6 on human meta-
phase spreads. (a) Metaphase showing the typical dual signal on
chromosome 11. (b) A G-banded version of (a). (c) A labelled
chromosome 11 and an 11 ideogram.
Figure 6 In situ PCR analysis of the PSM gene using a 129 bp
5' end fragment on a human metaphase spread. The chro-
mosome 11 signal is arrowed.
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or DU-145. Given the possible presence of a second PSM-
related gene. it may be difficult to demonstrate deletion of
the PSM gene itself at present in PC-3 and DU-145 cell lines
as any PSM probe might cross-hybridise in Southern blots.
Analysis of metaphase spreads prepared from these cell lines
by FISH or PRINS may be informative in this regard.
The tissue specificity of PSM expression has been reported
using ribonuclease protection assays (Israeli et al., 1994).
Expression levels are highest in normal human prostate, as
well as in primary and secondary prostatic tumours. Small
amounts of message are present in brain, salivary gland and
small intestine. Transcription or translation of any putative
PSM-related gene would not necessarily have been detected
using either PSM-specific riboprobes in ribonuclease protec-
tion assays or the monoclonal antibody 7E1 1-C5. The
available monoclonal antibody may not be cross-reactive
with the PSM-related protein as this may have a different
carbohydrate signature. There is, however, a risk that by
simply raising monoclonal antibodies against PSM peptide
epitopes cross-reactivity with the PSM-related protein may
emerge. Furthermore, a number of bands larger than
100.5 kDa are seen on Western blots of LNCaP (Israeli et al..
1994). The known splice variants of PSM generate mRNAs
which would be expected to generate smaller proteins than
PSM itself (see below). Thus. although these larger species
may be additional splice variants of PSM or reflect alterna-
tive glycosylation profiles for the protein, it is conceivable
that they are the expression products of another closely
related gene. In summary, previous Western blotting studies
do not rule out the possibility of the presence of a PSM-
related gene or of its expression.
More recently, alternative splicing of the PSM mRNA has
been described (Heston. 1994). This has been shown to
generate a shortened mRNA. designated PSM' of 2387
nucleotides compared with the 2653 nucleotides of PSM.
These RNAs are identical except for a deletion of 266 bases
between residues 114 and 380 of the PSM message near its 5'
end. This region contains the PSM translation initiation
codon and the codons for the PSM transmembrane domain.
It has therefore been suggested that PSM' is a cytosolic
protein. Interestingly. PSM is the predominant mRNA
species in prostatic tumour tissue and in the LNCaP cell line.
Normal prostatic tissue. however, mainly contains the PSM'
mRNA. The relative ratios of PSM to PSM' message in
malignant tissue, benign prostatic hypertrophy and normal
prostatic tissue are approximately 10. 1 and 0.1 respectively.
The effect of expression of PSM as opposed to PSM' on
tumour progression remains to be established. There is no
suggestion that PSM' represents expression from another
genetic locus. Whether a second related gene could provide a
PSM-like function in normal prostatic tissue or a PSM'
function in malignant tissue also remains to be established.
The identification of two distinct genetic loci on chro-
mosome 11 is unlikely to be artefactual. It is unlikely that the
cross-reactivity is due to other sequences within YAC 13BE6
because the Southern blot data suggest that the genome does
contain an additional gene or genes with homology to the
N-terminal cDNA PCR fragnent used in screening (Israeli et
al., 1993). Although the 129 bp cDNA PCR fragment used as
a probe contains the whole of the PSM transmembrane
domain, half of the probe is constituted by the sequence
encoding the cytosolic 19 amino acid residues, and this
sequence is likely to be unique. Furthermore, the YAC
13BE6 will contain the 450 bp segment of the PSM gene
which shows 55% homology with the human transferrin
receptor mRNA (Keer et al.. 1990; Rossi and Zetter. 1992).
Thus, if this YAC were undergoing cross-hybridisation from
short sequences within it. an artefactual signal might have
been expected on human chromosome 3q where the transfer-
rin receptor is localised. No such signal was detected (see
Figure 5).
Chromosome 11 has not previously been widely suggested
as the location of possible tumour-suppressor genes which
are consistently deleted in prostatic cancer. Most evidence
has previously implicated regions such as 8p22. 16q22 and
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1Oq24 as well as various other loci in this context (Isaacs and
Carter. 1991). The chromosome sublocalisation and PRINS
data strongly suggesting that PSM itself is localised at
lI p1 1.2 are very interesting in the context of recent observa-
tions bv Isaacs and co-workers. They identified a region on
human chromosome 1p11.2'-p13 which suppressed metas-
tasis in rat prostatic carcinoma cells (Ichikawa et al.. 1992).
This metastasis-suppressor activity had no effect on tumor-
igenicity or tumour growth rate. demonstrating that the
encoded activities were distinct from effects of tumour supp-
ression itself. The metastasis-suppressing activity of this
human chromosome 11 region seems to be specific for pros-
tatic cancers. and the metastatic abilitv of rat mammary
cancer cell lines was not suppressed. Thus. it is possible that
PSM has a role in the suppression of metastasis in prostatic
cancer. It has been shown that reduction in androgen levels
leads to an increased level of expression of PSM at least in
LNCaP prostatic cancer cells (Israeli et al.. 1994). Thus.
orchidectomy and androgen ablation may conceivably exert
part of their clinical effect bv driving increased PSM expres-
sion and reducing the metastatic tendency. It should be noted
that mapping of metastatic-suppressor activity to the
llpll.2-13 region by microcell-mediated transfer does not
establish whether PSM or PSM' (or both) are the functional
metastasis-suppressor proteins, if indeed either of them is
involved.
The treatment of LNCaP cells with 5a-dih drotestosterone.
testosterone. oestradiol or progesterone reduces the level of
expression of PSM up to 10-fold (Israeli et al.. 1994). Expres-
sion seems not to be reduced by dexamethasone or retinoids.
Thus. PSM is strongly expressed in both anaplastic and
hormone refractory lesions. Therefore the Cyt-356 antibody
may be particularly useful in identifying and targeting such
lesions. This is in contrast w%ith PSA. whose expression is
decreased folloWinz hormone withdrawal (Henttu et al..
1992).
A number of growth factors and their receptors are ex-
pressed by prostate tumour epithelial cells. These include
both transforming growth factor alpha (TGF-x) and the
epidermal growth factor (EGF) receptor. Both EGF and
TGF-a increase the expression of PSM mRNA by some
8-fold in LNCaP cells in culture in androgen-depleted
medium (Heston. 1994). Again. this is in contrast to the
expression of PSA induced by these grow-th factors. which is
markedlv down-regulated. Tumour necrosis factor (TNF-x)
and TNF-P both caused an 8-fold reduction in PSM
messenger RNA levels. It is known that TGF-a is mitogenic
for aggressive prostatic cancer as well as normal prostatic
epithelium. Given that these experiments were conducted on
LNCaP cells. all of these effects on expression levels refer to
the full-length PSM mRNA and not to PSM'. Normal pros-
tatic epithelium does not express basic fibroblast growth
factor (bFGF) or the bFGF receptor. This is in contrast to
the situation in prostatic cancer cells, which usually express
both of these species (Yan et al.. 1993). Treatment of LNCaP
cells in culture with bFGF has been shown to result in a
1000% increase in expression levels of PSM messenger RNA
(Heston. 1994). The significance of this in vivo remains to be
established. Again. the effect of bFGF on expression of PSM'
remains unknown. bFGF may potentially have a clinical role
bv increasing the levels of PSM on prostatic cancer cells in
Viho before treatment with radioactivelv labelled Cvt-356 for
therapy (Axelrod et al.. 1992).
Indium-l 11-labelled Cyt-356 is now in phase III clinical
trials in the USA as an imaging agent for prostatic cancer
(Lopes et al.. 1990; Wynant et al.. 1991: Rochon et al.. 1994).
Itrium-90-labelled Cyt-356 is about to enter phase II studies
as a potential therapeutic modality to target metastatic pros-
tate cancer cells (Axelrod et al.. 1992). This isotope is a
A-emitter and has apparently shown some myelosuppression
in phase I studies. RT-PCR based assays for PSM (as
opposed to PSM') has been shown to correlate with the
presence of disseminated disease (Heston. 1994). Full charac-
terisation of the PSM promoter is in progress with a view to
using it to drive tissue-specific expression of. for example.
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cytosine deaminase specifically in prostatic tissue. This may
allow treatment with 5-fluorocytosine at high doses so that
the cytotoxic 5-fluorouracil is generated exclusively in pros-
tatic tissue in patients. Given this intensive scientific and
clinical activity, it seems prudent to now attempt to clone
and characterise this other gene (or genes) related to PSM on
human chromosome 11. Although the related gene may be
an unexpressed pseudogene, it is important that this is estab-
lished so as to complete our understanding of this imp'ortant
protein and its role in the aetiology of human prostate
cancer.
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